Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado lowered its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 9.5% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,066 shares of the biotechnology company’s stock after selling 956 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Sarepta Therapeutics were worth $1,432,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Principal Securities Inc. acquired a new stake in Sarepta Therapeutics in the fourth quarter valued at approximately $26,000. Mather Group LLC. acquired a new stake in Sarepta Therapeutics during the 1st quarter valued at $28,000. Riggs Asset Managment Co. Inc. grew its holdings in Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 125 shares in the last quarter. Innealta Capital LLC purchased a new stake in Sarepta Therapeutics during the 2nd quarter worth $31,000. Finally, New Covenant Trust Company N.A. acquired a new position in Sarepta Therapeutics in the 1st quarter worth $32,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Sarepta Therapeutics news, Director Michael Andrew Chambers acquired 37,038 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 16th. The stock was bought at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the transaction, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $125.49 on Wednesday. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. The firm’s 50 day moving average is $136.24 and its two-hundred day moving average is $132.79. The firm has a market capitalization of $11.86 billion, a P/E ratio of 1,140.82 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 52 week low of $55.25 and a 52 week high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.01 by $0.06. The firm had revenue of $362.90 million for the quarter, compared to analysts’ expectations of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. Sarepta Therapeutics’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.27) EPS. Analysts anticipate that Sarepta Therapeutics, Inc. will post 1.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on SRPT. Piper Sandler dropped their target price on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Evercore ISI raised Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and cut their target price for the company from $185.00 to $179.00 in a research report on Thursday, August 8th. Leerink Partners raised their price target on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, June 24th. Citigroup cut their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, September 19th. Three investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $187.39.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.